Nonetheless, overexpression of PDE4 in the mouse liver is sufficient to trigger NAFLD and hypertension and can be avoided and even reversed by roflumilast PDE4-I [151]. Here, PDE4A is linked to metabolic dysfunction-associated steatotic liver disease.